scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00280-007-0603-8 |
P698 | PubMed publication ID | 17899082 |
P50 | author | Jan H Beumer | Q49531403 |
Timothy Synold | Q78536675 | ||
Heinz-Josef Lenz | Q89668545 | ||
P2093 | author name string | James H Doroshow | |
Merrill J Egorin | |||
Edward M Newman | |||
Robert A Parise | |||
P433 | issue | 2 | |
P921 | main subject | cytotoxicity | Q246181 |
P304 | page(s) | 363-368 | |
P577 | publication date | 2007-09-26 | |
P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
P1476 | title | Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) | |
P478 | volume | 62 |
Q37254998 | A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer |
Q35130668 | A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine |
Q34168766 | Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia |
Q58617093 | Biodistribution, tumor detection and radiation dosimetry of F-18 5-Fluoro-2'-Deoxycytidine (F-FdCyd) with Tetrahydrouridine in solid tumors |
Q37851012 | Cancer epigenetics reaches mainstream oncology |
Q36599581 | Chromatin deregulation in disease. |
Q61446834 | Clinicopathological and prognostic significance of hypermethylation in hepatocellular carcinoma: a meta-analysis |
Q26783596 | Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review |
Q34972245 | DNA demethylating antineoplastic strategies: a comparative point of view |
Q36986433 | DNA methylation: its role in cancer development and therapy |
Q37602208 | DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. |
Q37701947 | Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? |
Q36523796 | Digging deep into "dirty" drugs - modulation of the methylation machinery |
Q35750354 | Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine |
Q37962013 | Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers |
Q26828724 | Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments |
Q35162148 | Epigenetic therapy for breast cancer |
Q37964702 | Epigenetic-based therapies in cancer: progress to date |
Q39358434 | HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276). |
Q84325850 | Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase |
Q36706248 | Improving nucleoside analogs via lipid conjugation: Is fatter any better? |
Q36589313 | Inhibition of cancer cell proliferation by 5-fluoro-2'-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway |
Q38838257 | LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. |
Q34324930 | Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine |
Q38240032 | Oncometabolites-driven tumorigenesis: From genetics to targeted therapy |
Q36070627 | Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans |
Q26751251 | Orchestrating epigenetic roles targeting ocular tumors |
Q34195332 | Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. |
Q36480084 | Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors |
Q37962596 | Promises and challenges of anticancer drugs that target the epigenome |
Q33773171 | Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination |
Q46417113 | Synthesis and antiproliferative activities of 5-azacytidine analogues in human leukemia cells |
Q55435258 | Targeting DNA Methyltranferases in Urological Tumors. |
Q37320354 | Targeting DNA methylation |
Q34258037 | Targeting DNA methylation for epigenetic therapy |
Q26778508 | The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review |
Q38119782 | The promise and failures of epigenetic therapies for cancer treatment |
Q38257126 | Translational research in oncology--10 years of progress and future prospects |
Search more.